Technical Analysis for ALRN - Aileron Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 0.8941 -3.13% -0.03
ALRN closed down 3.13 percent on Friday, September 20, 2019, on approximately normal volume.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Down
See historical ALRN trend table...

Date Alert Name Type % Chg
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Calm After Storm Range Contraction -3.13%
NR7 Range Contraction -3.13%
NR7-2 Range Contraction -3.13%
Upper Bollinger Band Walk Strength -3.13%
Bearish Engulfing Bearish -5.88%

Older signals for ALRN ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Aileron Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation. The Company is advancing its lead oncology program to deliver efficacy and safety in a spectrum of solid and hematological malignancies. Its lead product candidate, ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers. The Company is conducting an ongoing Phase I clinical trial of ALRN-6924 in adult patients with solid tumors or lymphomas expressing non-mutated or wild-type p53 that are refractory to or intolerant of standard therapy. ALRN-6924 may reactivate p53-mediated cell death by targeting both of the natural p53 suppressor proteins, Mouse double minute 2 homolog (MDM2) and MDMX.
Biopharmaceutical Cancer Biology Solid Tumors Cancers Inflammation Molecular Biology Tumor Cell Biology Metabolic Diseases Proteins Oncogenes Lymphomas
Is ALRN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 3.23
52 Week Low 0.445
Average Volume 353,755
200-Day Moving Average 1.1975
50-Day Moving Average 0.6782
20-Day Moving Average 0.8433
10-Day Moving Average 0.9169
Average True Range 0.0899
ADX 31.9
+DI 24.9404
-DI 17.633
Chandelier Exit (Long, 3 ATRs ) 0.7803
Chandelier Exit (Short, 3 ATRs ) 0.9297
Upper Bollinger Band 1.0323
Lower Bollinger Band 0.6543
Percent B (%b) 0.63
BandWidth 44.823906
MACD Line 0.0746
MACD Signal Line 0.0702
MACD Histogram 0.0044
Fundamentals Value
Market Cap 13.16 Million
Num Shares 14.7 Million
EPS -41.73
Price-to-Earnings (P/E) Ratio -0.02
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.12
Resistance 3 (R3) 1.14 1.08 1.08
Resistance 2 (R2) 1.08 1.02 1.07 1.07
Resistance 1 (R1) 0.99 0.99 0.96 0.97 1.06
Pivot Point 0.93 0.93 0.91 0.92 0.93
Support 1 (S1) 0.84 0.87 0.81 0.82 0.73
Support 2 (S2) 0.78 0.84 0.77 0.72
Support 3 (S3) 0.69 0.78 0.71
Support 4 (S4) 0.67